“But with that said, we are still targeting the top line data by the end of the year for ADEPT-2.”

In context

“am. Samit Hirawat: Yes. Thanks, Adam, and thank you, Chris, for the question as well. The Cobenfy, from Alzheimer disease perspective, we remain confident in the product and certainly are conducting all our clinical trials with that mindset, not only in the psychosis program, but also for agitation as well as cognition. For ADEPT-2, we're certainly looking forward to the database lock, and we remain blinded to that data at this time. As Chris mentioned earlier during his prepared remarks, we are also reviewing our key studies to make sure that internally, we give the highest probability of success to all of our programs. And specifically, as it relates to ADEPT-2 in preparation of that database lock, we are conducting the clinical trial site reviews that could impact the time lines a bit. But with that said, we are still targeting the top line data by the end of the year for ADEPT-2. As far as the filing is concerned, as I think as we mentioned already, we are conducting 3 studies in Alzheimer's Disease Psychosis, ADEPT-2, ADEPT-4, ADEPT-1. ADEPT-4 and ADEPT-1 will read out in 2026. And so 2 of the 3 studies need to be positive for us to be engaging the health authorities for a filing and registration purposes. We are glad where we are in terms of our enrollments and looking forward to the data readouts. Operator: The next question will come from Evan Seigerman with BMO. Evan David Seigerman: I wanted to touch on some of the rationale for partnering with BioNTech. And specifically, what you saw in their PD-L1 VEGF bispecific. There's a lot of assets out there. What attracts you to the partnership with them? Maybe walk me through some of the differentiation and how you”